Microvascular Disease Articles & Analysis: Older
6 news found
Sonavex scored FDA clearance for its technology that uses ultrasound imaging and deep learning to deliver blood flow data on demand. The EchoSure system is cleared for use with the company’s EchoMark bioresorbable tissue markers, which got the agency’s nod in June. “The key goal is to be able to detect the problems associated with microvascular and vascular surgeries with ...
Occlusion of these small vessels (coronary microvascular disease) can diminish blood flow to the heart leading to chest pain or shortness of breath, as well as diffuse chest discomfort similar (and often as debilitating) to those from classic Coronary Artery Disease (CAD). This presence of angina with minimal or no angiographic CAD is referred ...
Gesynta Pharma AB ("Gesynta"), a clinical stage company developing novel anti-inflammatory agents, today announced that the results from the successfully completed First-in-Human clinical study with its lead candidate GS-248 for the treatment of microvascular disease have been presented at the EULAR 2020 E-Congress. Following these results, Gesynta now intends ...
GS-248 is a potent and selective inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1) in development for the treatment of microvascular diseases in chronic inflammatory conditions. Preclinical studies demonstrate that inhibition of mPGES-1 provides a combination of anti-inflammatory, vasodilatory and platelet inhibitory effects. "The results obtained ...
” CLI is a serious form of peripheral artery disease (PAD), a condition that affects more than 200 million people worldwide and results in the narrowing of blood vessels and reduced blood flow to the lower limbs. ...
This enables evaluation for the treatment of several cardiovascular diseases. GS-248 is initially being developed for treatment of microvascular diseases in chronic inflammatory conditions. ...